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ORIGINAL ARTICLE
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ABSTRACT
Background: The primary objective of this study was to compare the progression-free survival (PFS) at
12 weeks between patients treated with IGF-1R pathway modulator AXL1717 (AXL) and patients
treated with docetaxel (DCT).
Material and methods: The study was conducted at 19 study centers in five countries. A total of
99 patients with previously treated, locally advanced or metastatic non-small cell lung cancer (NSCLC)
of the squamous cell carcinoma (SCC) or adenocarcinoma (AC) subtypes in need of additional treat-
ment were randomized and treated with either 300 or 400mg of AXL as daily BID treatment (58
patients) or DCT given as 75mg/m2 in three-week cycles (41 patients) as monotherapy in a 3:2 ratio
for each NSCLC subtype. Patients were treated in the primary study treatment period for a maximum
of four treatment cycles.
Results: The 12-week PFS rate, median PFS and overall survival (OS), as well Kaplan-Meier hazard ratio
for PFS and OS, did not show any statistically significant differences between the treatment groups.
For the primary endpoint, the AXL group had a lower percentage of patients (25.9%) who were pro-
gression-free at Week 12 as compared to the DCT group (39.0%), although the difference was not stat-
istically significant. The most notable difference in the incidence of treatment emergent adverse effects
(TEAEs) was the lower incidence of treatment-related grade 3/4 neutropenia in patients treated
with AXL.
Conclusion: These results suggest neither of the treatments to be superior of the other when treating
locally advanced or metastatic NSCLC. Considering the lower incidence of grade 3/4 neutropenia in the
AXL group this treatment warrants further research.
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Lung cancer is today the most common cancer and also
the leading cause of cancer-related death in the western
world [1]. Patients with advanced disease who relapses after
initial therapy are often given docetaxel (DCT) [2]. The prog-
nosis is dismal with five-year survival rates of <5% for these
patients [3].
The insulin-like growth factor 1 receptor (IGF-1R) signaling
pathway is considered to be a valid target for anticancer
pharmaceutical development. The relatively high levels of
free IGF-1 in adenocarcinoma (AC) and squamous cell carcin-
oma of the lung (SCC) suggest these cancers to be the
potentially promising areas for development of drugs that
target the (IGF-1R) signaling pathway [4–9].
AXL1717 (AXL) is an oral small-molecule pharmaceutical
agent, originally developed as a targeted modulator of (IGF-
1R) signaling [10]. Its anti-tumoral effect is suggested to
derive from indirect effects on microtubule dynamics leading
to cell cycle arrest in mitosis and subsequent mitotic
catastrophe. Based on the absence of direct binding to beta-
tubulin and on the benign clinical side effect profile, the
effect on microtubule seems to differ from microtubule
inhibitors presently used clinically [11,12]. Several anti-IGF-1R
antibodies have been tested clinically against a wide range
of cancers, including lung cancer, with disappointing results
[13,14]. The dual mechanism of AXL (IGF-1R modulation and
cell cycle arrest) may therefore provide a mechanism for anti-
tumoral activity of clinical interest.
In the present randomized phase II study, a total of
99 patients with previously treated, locally advanced or meta-
static SCC or AC subtypes of non-small cell lung cancer
(NSCLC) were randomized in 3:2 ratio for each NSCLC sub-
type, to either DCT as monotherapy or AXL as monotherapy
with the primary aim of comparing the rate of progression-
free survival (PFS) at 12 weeks.
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Material and methods
The study was designed as an open-label, randomized, multi-
center, phase II study to compare AXL to standard DCT as
second-line treatment of SCC and AC of the lung. Also third-
line treatment was allowed in the AC group. An overview of
the study design and patient disposition is shown in
Figure 1. The study has been registered in ClinicalTrials.gov
(NCT01561456).
Patients with histologically confirmed diagnosis of locally
advanced, or metastatic (stage IIIB or IV) SCC or AC histologic
subtype of NSCLC who had received one (SCC) or one or two
(AC) previous lines of antitumor treatment were included.
The first patient was included 19 December 2011 and the
study was terminated 1 September 2013.
Based on results from clinical trials reported by Shepherd
and Fossella [15,16], a 12-week PFS of 42.6% was expected
with DCT in second-line NSCLC treatment. It was suggested
by Regulatory Authorities to design this phase II study with
50% power for the assessment of the primary endpoint as
the study was performed in a phase II setting. In the original
protocol, an expected overall sample size of 140 provided
50% power to find a statistically significant difference at the
5% level (two-sided test), with 84 patients in the AXL group
and 56 patients in the DCT group, if the PFS rate with AXL
was 61.1%. An interim review of efficacy data in May 2013
showed that OS results were supportive of comparability of
AXL to standard treatment with DCT, and as the probability
for either treatment to show superiority over the other with
respect to OS was regarded as low, the Sponsor curtailed
enrollment in the study from a planned 140 treated patients
to the 99 patients described in this report. At the end of the
screening period, when a patient was determined to be eli-
gible for enrollment, the site contacted the interactive web-
based randomization system (IWRS) and the patient was
assigned a patient number and was randomly allocated to
either the AXL group or the DCT group. No blinding of study
medications was performed.
Randomization with stratification (SCC and AC subtypes of
NSCLC) was used to avoid bias in assigning patients to
Figure 1. Study flow diagram.
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treatment, to increase the likelihood that known and
unknown patient attributes (e.g. demographics and baseline
characteristics) were evenly balanced across treatment
groups, and to enhance the validity of statistical comparisons
across treatment groups. Patients were to be randomized to
either AXL or to DCT as monotherapy in a 3:2 ratio for each
NSCLC subtype.
The study was subject to initial and continuing ethical
review by an Institutional Review Board (IRB) and
Independent Ethics Committee (IEC).
The study was conducted at 19 study centers: Belarus (1),
Hungary (3), Poland (1), Russia (6), and Ukraine (8). Before ini-
tiation of the study at each investigative site, the protocol,
the informed consent form(s), the patient information sheet,
details of patient recruitment, and any other relevant study
document were submitted to the responsible ethics commit-
tees and written approvals were obtained.
Patients were treated in the primary study treatment
period for a maximum of four treatment cycles. A treatment
cycle in the primary period was 21 days, unless dose delay or
dose interruption was required. Patients treated with AXL,
who responded to treatment or remained stable at the end
of four cycles in the primary treatment period could be
offered an extension of treatment with AXL. Such extension
treatment was initiated by the Investigator and decided in
consultation with the Sponsor on a case-by-case basis.
Extension treatment cycles were 42 days with the same dose
as in the primary study period (28 days of AXL treatment fol-
lowed by a 14-day treatment-free interval), and the extension
period could continue for up to four extension cycles
(22 weeks) as long as the patient continued to benefit from
AXL treatment.
AXL was provided in a ready-to-use suspension for oral
administration. In the original protocol, AXL was administered
as 400mg given twice daily (BID) for the first 21 days of each
cycle. Following safety concerns addressed in Protocol
Amendment 2, AXL was administered as 300mg for the first
28 days (21 days in Cycle 1 and the first seven days of Cycle
2). Then, depending on ANC levels measured during the first
28 days, subsequent doses could be increased to 400mg
BID, remain at 300mg BID, or be temporarily interrupted
and, when ANC levels recovered to an acceptable level, be
resumed at the same dose or one dose level lower.
DCT was administered as a standard 75mg/m2 in 100ml
of normal saline solution with intravenous (IV) infusion over
60minutes on Day 1 of each 21-day treatment cycle for up
to four cycles, according to local institutional procedures
and standards. All patients receiving DCT were to be pre-
medicated with corticosteroids, such as dexamethasone,
according to local standard of care in order to reduce the
incidence and severity of fluid retention as well as the sever-
ity of hypersensitivity reactions. Dose delays and adjustments
were made for toxicities.
The primary objective of the study was to compare the
rate of PFS at 12 weeks between patients treated with AXL
and patients treated with DCT in the total study population
and in the SCC and AC subtypes of NSCLC. PFS was defined
as the time from randomization to the first observation of
disease progression according to the RECIST criteria or death
due to any cause. Patients were considered to be progres-
sion-free if they had a valid 12-week assessment by the cen-
tral reviewer resulting in complete response (CR), partial
response (PR) or stable disease (SD). Computed tomography
(CT) scans performed between Days 56 and 113 were
regarded as valid assessments for the primary endpoint. If no
central assessment was available, a suitable local assessment
was used instead.
Tumor assessment was performed at baseline and then at
the end of Cycles 2 and 4. RECIST assessments of images
related to the primary endpoint (baseline and the 12-week
assessment) were repeated by a central independent radiolo-
gist as confirmation during the primary treatment period.
During the extension period, RECIST assessments were con-
ducted locally after Extension Cycles 2 and 4 (10 and
22 weeks) or at clinical signs of tumor progression at the dis-
cretion of the Investigator. Disease progression and survival
status were obtained for all patients until death or the end
of the study.
Safety evaluations included ongoing monitoring of
adverse events (AEs), vital signs, physical examinations, clin-
ical laboratory tests and electrocardiographies (ECGs). Safety
during the conduct of the trial was monitored by the data
safety monitoring committee (DSMC).
The DSMC was an independent, multidisciplinary advisory
group responsible for the safety of the study patients. It was
composed of senior biomedical and statistical experts with
experience in the conduct of clinical studies, especially in
studies for NSCLC. The DSMC provided recommendations
about stopping or continuing the study, modifications of the
AXL dose, or an alternate AXL treatment schedule, if needed.
All data were processed and summarized by the use of
SASVR Version 9.0 or higher. All statistical tests were two-sided
at the 0.05 level of significance.
Results
Antitumor efficacy
The patient baseline characteristics are shown in Table 1. The
primary endpoint of the study was the PFS rate at 12 weeks
as assessed by an independent blinded reviewer. PFS rate
was defined as the proportion of surviving, non-progressing
patients at 12 weeks (±4 weeks). Patients with no data for
assessment of PFS at 12 weeks (early discontinued, death,
tumor assessment was not done or not available, and other
reasons) were classified as progressed (non-responders).
For the primary endpoint, 15 patients (25.9%) the AXL
group were progression-free at the 12-week assessment com-
pared with 16 patients (39.0%) in the DCT group (p¼ 0.191).
Of interest is that the disease progression at 12 weeks was
roughly similar in the two groups with 13 patients (22.4%) in
the AXL compared with seven patients in the DCT group
(17.1%). Reasons for the differences included death prior to
the 12-week assessment (20.7% compared with 12.2%, AXL
vs. DCT) and assessments outside of the protocol window
(13.8 vs. 7.3%). Six early fatal events in the AXL group were
assessed as being related to AXL treatment as discussed
under the safety section.
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PFS was also estimated with the Kaplan-Meier procedure.
These data are displayed in Figure 2. The median overall sur-
vival (OS) was 38.7 in the AXL group compared with 37.4
weeks in the DCT group with a hazard ratio of 0.904
(p¼ .664). The OS data assessed by the Kaplan-Meier
procedure showed similar OS for the AXL-treated patients in
comparison to the DCT cohort for all patients as well as for
the patients in the subgroups of AC and SCC.
RECIST tumor response assessed by a central independ-
ent blinded reader at 12 weeks showed that no patient
had a CR in either treatment group. A total of five PRs
were found by the central reader at the 12-week assess-
ment in the DCT group compared with none in the AXL
group (p¼ .010). The objective response rate (CRþ PR) at
12 weeks by central reader was thus significantly lower
(p¼ .010) for the AXL group (0.0%) compared to the DCT
group (12.2%). The disease control rate (CRþ PRþ SD) by
central reader was 24.1% for the AXL group and 36.6% for
the DCT group (p¼ .189).
Safety
The grade 3/4 AEs were more common in the DCT group
with 51% of the patients reporting at least one grade
3/4 adverse event compared with 41% in the AXL group
(Table 2). The main side effects in both groups were bone
marrow related with neutropenia (leukopenia) being the
dominating in the adverse event profile. The laboratory data
showed that 22% of the AXL-treated patients reported at
least one occurrence of grade 3/4 neutropenia compared
with 54% in the DCT group. Hyperglycemia was observed in
one patient in the AXL group (1.7%) and in no patients in
the DCT group.
In the AXL treatment group, the serious treatment emer-
gent adverse effects (TEAEs) that occurred in 5% of the
patients were neutropenia (8.6%) and leukopenia (5.2%). All
of the occurrences of these events were related to treatment.
In the DCT treatment group, serious neutropenia occurred in
4.9% of the patients; no incidences of serious leukopenia
occurred in the DCT treatment group. All of the occurrences
of serious neutropenia in the DCT group were related to
treatment.
Table 1. Baseline characteristics.
Parameters AXL N¼ 58 DCT N¼ 41 Total
Median age (years); (Min/Max) 57 (42/81) 58 (44/73) 57 (42/81)
Sex, n (%)
Female 18 (31.0) 10 (24.4) 28 (28.3)
Male 40 (69.0) 31 (75.6) 71 (71.7)
Previous cancer treatment, n (%)
Chemotherapy 58 (100) 41 (100) 99 (100)
Surgery 19 (32.8) 14 (34.1) 33 (33.3)
Radiotherapy 4 (6.9) 10 (24.4) 14 (14.1)
ECOG performance, n (%)
0 12 (20.7) 12 (29.3) 24 (24.2)
1 43 (74.1) 28 (68.3) 71 (71.7)
2 3 (5.2) 1 (2.4) 4 (4.0)
Histologic subtype N¼ 58 N¼ 41
AC 29 (50.0) 20 (48.8) 49 (49.5)
SCC 29 (50.0) 21 (51.2) 50 (51.5)
T classification1 N¼ 58 N¼ 41
T1a 1 (1.7) 3 (7.5) 4 (4.0)
T2 29 (50.0) 16 (40.0) 45 (45.5)
T3 10 (17.2) 14 (35.0) 24 (24.2)
T4 9 (15.5) 3 (7.5) 12 (12.1)
T4a 8 (13.8) 4 (10.0) 12 (12.1)
Tx 1 (1.7) 1 (2.5) 2 (2.0)
N classification1 N¼ 58 N¼ 41
N0 7 (12.1) 3 (7.5) 10 (10.1)
N1 7 (12.1) 8 (20.0) 15 (15.2)
N2 26 (44.8) 18 (45.0) 44 (44.4)
N3 16 (27.6) 10 (25.0) 26 (26.3)
Nx 2 (3.4) 2 (4.9) 4 (4.0)
M classification1 N¼ 58 N¼ 41
M0 17 (29.3) 13 (31.7) 30 (30.3)
M1 37 (63.8) 25 (61.0) 62 (62.6)
Mx 4 (6.9) 3 (7.3) 7 (7.1)
Current tumor status1 N¼ 58 N¼ 41
Metastatic 52 (89.7) 40 (97.6) 92 (92.9)
Locally advanced 6 (10.3) 1 (2.4) 7 (7.1)
1TNM classification refers to initial diagnosis. Current tumor status refers to
study baseline.
Figure 2. Kaplan-Meier plot for overall survival.
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Fatal events
A total of 17 deaths in the study were related to TEAEs. Of
these, 12 occurred in the AXL group (21%) and five in the
DCT group (12%). Disease progression was related to three
deaths in the AXL group (5%) and four in the DCT group
(10%), events with neutropenia were related to five deaths in
the AXL group only (9%), and pulmonary bleeding was
related to two deaths in the AXL group only (3%). Other rea-
sons (respiratory failure; heart and respiratory failure) were
reported for two patients in the AXL group (3%) and one
patient (pulmonary edema) in the DCT group (2%).
The events with neutropenia that led to death for five
patients in the AXL group were assessed as related or pos-
sibly related to study treatment. Of the remaining 12 deaths
related to TEAEs, the fatal events were assessed as not
related to study treatment.
Following the deaths of 12 patients in the study (nine in
the AXL group and three in the DCT group), with seven
patients dying within four weeks of entry into the study,
enrollment was temporarily suspended while the DSMC con-
vened three times and reviewed the cases and recom-
mended an amendment to the protocol (7 October 2012).
The deaths included four cases of neutropenia, of which
three were not treated with antibiotics but were treated with
corticosteroids, and two cases of pulmonary hemorrhage in
patients with central squamous tumors with tumor involve-
ment of major blood vessels on CT. In the amended protocol,
it was therefore stated that SCC patients with radiologically
verified involvement of the major vessels were to be
excluded and the management of patients with neutropenia
was described in a special document and guidelines with
respect to prophylactic antibiotic treatment and the use of
granulocyte colony-stimulating factors (G-CSF) in neutropenic
patients were provided to all study centers. In the original
protocol, the use of G-CSF was prohibited and led to with-
drawal from the study. However, after protocol amendments,
recommendations for treatment of neutropenic events with
G-CSF were specified. At the time recruitment was sus-
pended, 75 patients had been treated (46 AXL and 29 DCT).
After the review by the DSMC, 23 patients (14 AXL and 9
DCT) already randomized continued receiving study
treatment.
Discussion
In the present study, a total of 99 patients with previously
treated, locally advanced or metastatic NSCLC were random-
ized to either AXL (58 patients) or DCT (41 patients). The
results shows that median OS time was 38.7 weeks for
the AXL group and 37.4 weeks for the DCT group (p¼ .661),
thus no superiority of any the treatment groups could be
shown.
In the second-line setting, DCT was the first drug
approved clinical use based on the results of two phase III
trials which proved DCT to be superior to best supportive
care [15] and to treatment with vinorelbine or ifosfamide [16]
in terms of OS. Other drugs that have proven to be effective
in the second-line setting include pemetrexed (non-squa-
mous NSCLC) [17] and erlotinib [18]. Recently, promising data
has also emerged concerning the programed death 1 (PD-1)
immune-checkpoint–inhibitor antibody nivolumab that has
been shown to be superior to DCT in advanced NSCLC in the
second-line setting [19].
In a previous phase I/II study by Ekman et al., intermittent
treatment with AXL for up to 28-days with 14–21-day treat-
ment-free periods in between, was associated with RECIST-
confirmed tumor response in one patient with squamous
NSCLC [11]. In the present study, RECIST assessment at 12
weeks showed that no patients had achieved a CR in either
treatment group, whereas a total of five PRs were found in
the DCT group compared with none in the AXL group. There
was no statistically significant difference in the disease con-
trol rate (CRþ PRþ SD) between the AXL group and the DCT
group.
A major drawback of the present study that has to be
acknowledged is the lack of molecular characterization of the
tumors. As a consequence, we have no data on IGF-1R expres-
sion in the tumors of the treated patients. As IGF-1R is the
Table 2. Summary of grade 3/4 treatment emergent adverse events and treatment-related adverse events overall and by preferred term occurring
in two patients or more.
MedDRA Preferred term
AXL DCT
Overall n (%) Related n (%) Overall n (%) Related n (%)
N¼ 58 N¼ 58 N¼ 41 N¼ 41
Any TEAE 24 (41.4) 20 (34.5) 21 (51.2) 20 (48.8)
Blood and lymphatic system disorders 18 (31.0) 18 (31.0) 20 (48.8) 20 (48.8)
Neutropenia 15 (25.9) 15 (25.9) 17 (41.5) 17 (41.5)
Leukopenia 9 (15.5) 9 (15.5) 3 (7.3) 3 (7.3)
Anemia 6 (10.3) 6 (10.3) 1 (2.4) –
Agranulocytosis – – 2 (4.9) 2 (4.9)
General disorders and administration site conditions 5 (8.6) – 3 (7.3) 2 (4.9)
Fatigue 3 (5.2) – 2 (4.9) 2 (4.9)
Respiratory, thoracic, and mediastinal disorders 3 (5.2) 1 (1.7) 3 (7.3) 1 (2.4)
Dyspnea 1 (1.7) 1 (1.7) 2 (4.9) –
Pulmonary hemorrhage 2 (3.4) – – –
Infections and infestations 3 (5.2) 2 (3.4) – –
Neoplasms benign, malignant, and unspecified (including cysts and polyps) – – 2 (4.9) –
Nervous system disorders – – 2 (4.9) –
Vascular disorders 2 (3.4) – – –
Hypotension 2 (3.4) – – –
AXL: AXL1717; DCT: docetaxel; MedDRA: Medical Dictionary for Regulatory Activities; TEAE: treatment emergent adverse event.
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target of the study drug AXL, analysis and quantification of
IGF-1R expression in relation to survival could have provided
insight to whether IGF-1R expression in the tumor tissue could
be used as a predictive factor for response to AXL treatment.
In addition, IGF-1R expression has previously been found to
be prognostic in advanced NSCLC [20,21] which adds to its
importance in this setting. In the present study, there had
been discussion with the participating study centers regarding
the possibility to extract new tumor samples from the
included patients, however, only in one of the centers this
was deemed feasible and as that would only cover a small
proportion of the included patients it was considered not
enough to conduct meaningful analyses.
Another important remark on the design of the present
study is whether DCT is the most appropriate cytotoxic regi-
men to compare the study drug AXL with. In a phase III non-
inferiority designed clinical trial comparing pemetrexed
500mg/m2 every three weeks with DCT 75mg/m2 every
three weeks in patients with NSCLC previously treated with
chemotherapy, no statistically significant difference in PFS
and OS was observed but the incidence of grade 3/4 neutro-
penia and febrile neutropenia was significantly higher in the
DCT arm [17]. These results have led to an increasing use of
pemetrexed in combination with a platinum agent in the
first-line setting or as single-agent maintenance therapy in
patients with non-squamous histology [22], which has
reduced the availability of pemetrexed in the second-line set-
ting. Furthermore, the present study was conducted in 19
study centers in Eastern Europe in which the experience with
pemetrexed was greatly inferior to that with DCT, which also
contributed to choosing DCT as the chemotherapy to com-
pare AXL with in both AC and SCC patients.
The most commonly reported AEs in both treatment
groups were neutropenia, anemia, leukopenia and asthenia.
The overall incidence of AEs and especially the incidence of
neutropenia were higher in the DCT group as compared with
the AXL group. A total of 17 deaths related to SAEs occurred
within the primary study period: 12 in the AXL group and five
in the DCT group. Of nine early fatal cases in the AXL group,
four cases were connected to neutropenia and/or leucopenia.
These cases were reviewed in detail and it was found that
three patients were treated with corticosteroids (dexametha-
sone) during the neutropenic periods and two of the patients
were not treated with antibiotics as no fever was detected,
and additionally they remained outpatients during treatment.
This handling was considered inappropriate since steroids
may stimulate the growth of microorganisms by causing
immunosuppression, may mask fever and symptoms of infec-
tion, and do not stimulate host defense against microorgan-
isms. The discordance between the lower incidence of grade 3
or 4 neutropenia versus the higher incidence of fatal neutro-
penic events in the AXL group was thought to be partly due
to the daily dosing of AXL in contrast to once-every-three-
weeks dosing of DCT but also due to the suboptimal manage-
ment of these events, which could have been avoided with
prompt antibiotic treatment in an inpatient setting.
In the AXL group, two fatal events of pulmonary hemor-
rhage were reported as starting on 14 and 28 days after first
dose of AXL. Both patients had central squamous NSCLC
tumors with tumor involvement of major blood vessels on
CT which has been reported as risk factors for pulmonary
hemorrhage [23]. It was not possible to exclude that possible
tumor shrinkage could have contributed to the bleeding.
The results of the present study illuminate the difficulty of
treating patients continuously with a bone marrow toxic
medication. If the neutropenia is not detected early enough
with frequent blood sampling, the causative medication not
stopped early enough and appropriate treatment not given
early enough (antibiotics), then a manageable side effect
may turn into a fatal side effect. As no neutropenia as
occurred earlier that following 14 days of treatment with
400mg BID of AXL, future studies will explore treatment dur-
ation of AXL with seven days to avoid neutropenias while on
treatment. These studies will also explore seven-day dosing
with doses higher than 400mg BID of AXL.
In conclusion, the results from the present study failed to
show superiority of any of the treatment groups. This lack of
superiority does not preclude that the two treatments have
similar efficacy considering the study was not prospectively
designed to show similarity. However, both the OS and the
PFS Kaplan-Meier curves have a reasonable similar profile.
The lack of data on tumor IGF-1R expression unfortunately
prevented further analyses of whether the anti-tumoral effect
of AXL can be predicted based on the expression of the tar-
get molecule, IGF-1R. The safety profile displayed a lower
incidence of leukopenia and neutropenia in the AXL group
but a higher number of treatment-related fatal events. Given
these results, we believe that further clinical testing of AXL,
with evaluation of IGF-1R expression in tumor tissue as a pre-
dictive marker of treatment response, is warranted. Further
studies of AXL in combination with treatments targeting
other oncological pathways such as bevacizumab (anti-angio-
genesis) or nintendanib (tyrosine-kinase inhibition) could also
be an interesting approach.
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